Medicinova (MNOV) vs OKYO Pharma (OKYO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Medicinova (MNOV) has outperformed OKYO Pharma (OKYO) over the past year, gaining 26.2% versus a loss of 37.9%. Medicinova is the larger company by market cap ($75.8 million vs $72.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNOV | OKYO |
|---|---|---|
| Share price | $1.54 | $1.39 |
| Market cap | $75.80M | $72.95M |
| 1-day change | -4.35% | -2.73% |
| YTD return | +17.56% | -32.85% |
| 1-year return | +26.23% | -37.95% |
| 5-year return | -59.69% | — |
| EPS (TTM) | $-0.21 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.90 | $3.20 |
| 52-week low | $1.17 | $1.27 |
| Distance from 52-week high | -60.51% | -56.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +435.71% | +499.28% |
| Average volume | 322.57K | 93.79K |
| Shares outstanding | 49.22M | 52.48M |
| Employees | 6 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNOV has outperformed OKYO by 64.2 percentage points over the past year.
About Medicinova
MNOV stock →MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About OKYO Pharma
OKYO stock →OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
MNOV vs OKYO FAQ
Which is bigger, Medicinova or OKYO Pharma?
Medicinova (MNOV) is larger, with a market capitalization of $75.80M compared with $72.95M for OKYO Pharma (OKYO).
Which stock has performed better over the past year, MNOV or OKYO?
MNOV returned +26.23% over the past 12 months, compared with -37.95% for OKYO (price return, excluding dividends). Past performance does not predict future results.
Are Medicinova and OKYO Pharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Medicinova and Biotechnology: Biological Products (No Diagnostic Substances) for OKYO Pharma.